Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study
It is generally recommended that patients with splanchnic vein thrombosis (SVT) should receive a minimum of 3 months of anticoagulant treatment. However, little information is available on the long-term risk of recurrent thrombotic events. The aim of this study was to evaluate the risk of venous and...
Main Authors: | Nicoletta Riva, Walter Ageno, Daniela Poli, Sophie Testa, Serena Rupoli, Rita Santoro, Teresa Lerede, Antonietta Piana, Monica Carpenedo, Alberto Nicolini, Piera Maria Ferrini, Giuliana Martini, Catello Mangione, Laura Contino, Carlo Bonfanti, Paolo Gresele, Alberto Tosetto |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Gastroenterology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2015/620217 |
Similar Items
-
Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions
by: Nicoletta Riva, et al.
Published: (2020-03-01) -
Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette‐based survey
by: Nicoletta Riva, et al.
Published: (2020-10-01) -
Splanchnic Vein Thrombosis: Current Perspectives
by: Valeriani E, et al.
Published: (2019-10-01) -
COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis
by: Mateo Porres-Aguilar, et al.
Published: (2021-07-01) -
Splanchnic artery aneurysms
by: Davidović Lazar B., et al.
Published: (2006-01-01)